What is the Place for Uricosuric Agents in Gout Management?

Md Abu Bakar Siddiq*, Tim L. Jansen, Johannes J. Rasker

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

30 Downloads (Pure)


The auto-inflammatory rheumatic disorder gout is a worldwide problem [1]. It causes pain and loss of function when inadequately treated, leading to high costs and loss of productivity, income, and quality of life [1]. Gout is characterized by hyperuricemia and arousal of the NLRP3 (nucleotide-binding domain, leucine-rich repeat-containing proteins) inflammasome resulting in inflammatory arthritis and soft tissue rheumatism due to deposition of monosodium urate (MSU) crystals in joints and soft tissues around [2]. The clinical presentation of gout can be misleading, and other diseases can present in similar ways. In the elderly, gout is often not diagnosed as it frequently presents in the hands of elderly slim women and men [3]. The article focuses the gout management with particular attention to the uricosuric agents. Discussing anti-inflammatory medications details is our study limitation.
Original languageEnglish
Pages (from-to)279-285
Number of pages7
JournalCurrent rheumatology reviews
Issue number4
Publication statusPublished - Nov 2022


  • n/a OA procedure


Dive into the research topics of 'What is the Place for Uricosuric Agents in Gout Management?'. Together they form a unique fingerprint.

Cite this